Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
Koeberle D, Tschanz B, Rauch D, Peck-Radosavljevic M, Veilchenfeldt J, Lakatos G, Montemurro M, Wagner A, Buehlmann M, Horber D, Roth A, Saletti P, Samaras P, Ribi K, Li Q, Demeter G, Dufour J, Bodocky G. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol 2016; 27:856-861.
May 2, 2016
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
May 2, 2016
Ann Oncol 2016; 27:856-861
Koeberle D., Tschanz B., Rauch D., Peck-Radosavljevic M., Veilchenfeldt J., Lakatos G., Montemurro M., Wagner A.D., Buehlmann M., Horber Daniel, Roth A.D., Saletti P., Samaras P., Ribi K., Li Q., Demeter G., Dufour J.F., Bodocky G.
more
